Quantum Computing in Healthcare Companies

The global quantum computing in healthcare market is projected to reach USD 1,324.2 million by 2030 from USD 265.9 million in 2025, at a high CAGR of 37.9% during the forecast period. The quantum computing in healthcare market is experiencing significant growth, fueled by rising investments in both developed and developing regions. As global support for quantum technology accelerates, the healthcare sector is increasingly seen as a prime area for innovation, with the technology showing promise in transforming areas like drug development, diagnostics, genomics, and personalized medicine. Moreover, there is a noticeable trend among payers and insurers favoring quantum-driven approaches, highlighting a shift toward leveraging advanced computing for more efficient and outcome-focused healthcare delivery.

Two key strategies drive growth in the quantum computing healthcare market: technological innovation and strategic collaborations. On the innovation front, companies are advancing quantum algorithms to accelerate drug discovery and molecular simulation. For instance, in January 2025, Insilico Medicine, in collaboration with the University of Toronto, used IBM’s quantum systems to analyze over 1.1 million compounds for cancer treatment, significantly reducing computation time and identifying a promising anticancer candidate. In terms of strategic collaborations, tech firms and pharmaceutical companies are joining forces to integrate quantum computing into real-world healthcare applications. In June 2025, IonQ, AstraZeneca, AWS, and NVIDIA partnered to leverage quantum and AI technologies to enhance precision medicine. This collaboration highlights a broader industry trend towards high-performance, data-driven healthcare supported by next-generation computing.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the market include Rigetti & Co, LLC (US), IBM (US), D-Wave Quantum Inc. (Canada), Microsoft (US), IonQ (US), Quantinuum, Ltd. (US & UK), Google, Inc. (US), Atos SE (France), QC Ware (California), Classiq Technologies, Inc. (US), Xanadu Quantum Technologies Inc. (Canada), Hefei Origin Quantum Computing Technology Co., Ltd. (China), Protiviti, Inc. (US), Quandela (France), Deloitte (UK), Accenture (Ireland), Amazon Web Services (AWS) (US), Fujitsu (Japan), Qnami (Switzerland), SEEQC (US), SandboxAQ (US), Pasqal (France), Qubit Pharmaceuticals (France), Polaris Quantum Biotech (US), and QSimulate (US).

Rigetti & Co., LLC, a US-based quantum computing leader, develops integrated systems with applications in healthcare, including drug discovery and genomics. With research hubs in California and the UK, it focuses on superconducting qubit technologies and seamless quantum-classical integration via its Quantum Cloud Services (QCS) platform. The company emphasizes scalability, qubit performance, and AI compatibility and collaborates with life science firms to accelerate biomedical R&D. In April 2024, the company launched the Novera QPU Partner Program, enlisting leaders in cryogenics, control systems, software, and error correction, such as Bluefors, Quantum Machines, Classiq, and Riverlane, to support on-premise quantum deployment.

Amazon Web Services (AWS) is a key player in advancing quantum computing for healthcare through its Amazon Braket platform, which offers providers like IonQ, Rigetti, and Oxford Quantum Circuits access to quantum hardware. AWS supports hybrid quantum-classical workflows that enable researchers to tackle complex problems in drug discovery, molecular simulation, and precision medicine. Its global infrastructure and integration with AI/ML services help accelerate biomedical innovation by making quantum tools more accessible to pharma and biotech companies. AWS also collaborates with academic institutions, startups, and healthcare organizations to explore real-world applications of quantum computing in life sciences.

IBM is a global pioneer in quantum computing, actively advancing its role in the healthcare sector through hardware innovation, algorithm development, and cross-industry collaboration. The company’s IBM Quantum platform provides cloud-based access to some of the most powerful quantum processors, enabling researchers and healthcare institutions to experiment with quantum algorithms for drug discovery, protein folding, molecular interaction analysis, and optimization of clinical trials. IBM continues to expand its leadership in quantum computing for healthcare through innovative collaborations and technology milestones. In June 2024, IBM, alongside the Cleveland Clinic and the UK’s Hartree Centre, launched the Hartree National Centre for Digital Innovation, a joint venture leveraging AI and IBM Quantum computing to study clinical outcomes and identify biomarkers for epilepsy and other conditions.

MARKET RANKING

The quantum computing market in healthcare is becoming increasingly dynamic and competitive. Key players in this space include Rigetti & Co., LLC (US), IBM (US), D-Wave Quantum Inc. (Canada), Microsoft (US), IonQ (US), AWS (US), and Google (US), which together account for approximately 50–60% of the market share.

Rigetti is leading the charge with its hybrid quantum-classical computing platform and collaborations focused on drug discovery and molecular simulation, particularly through its Quantum Cloud Services. With a robust quantum infrastructure, IBM utilizes its Qiskit platform and maintains strong partnerships with healthcare leaders such as the Cleveland Clinic and Moderna, driving innovation in biomedical research and clinical applications.

D-Wave Quantum specializes in quantum annealing technology for healthcare-related optimization tasks, including clinical scheduling and treatment planning. IonQ is recognized for its high-accuracy trapped-ion quantum processors and is actively exploring applications in precision medicine, genomics, and AI-powered diagnostics.

AWS plays a crucial role through Amazon Braket, which offers access to a range of quantum hardware and supports quantum-classical hybrid solutions for drug development and molecular modeling. Its integration with AI/ML and cloud infrastructure makes it a favored partner for pharmaceutical and biotech firms. Meanwhile, Google continues to advance the field with its quantum processor and collaborations aimed at simulating complex biological systems and accelerating drug discovery.

The remaining 40–50% of the market is fragmented among emerging startups, academic initiatives, and regional providers. Market competition is driven by breakthroughs in hardware architecture and algorithm development, as well as an increasing demand from pharmaceutical and life science firms for quantum-powered tools in research and development and personalized treatment design.

Related Reports:

Quantum Computing in Healthcare Market by Component (Hardware, Software), Deployment (On-premises, Cloud-based), Technology (Superconducting Qubits, Trapped Ions), Application (Drug Discovery, Genomics), End User, and Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com